EW vs HAE
EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. HAE: Haemonetics provides essential technologies for blood and plasma collection, as well as specialized medical devices for hospital procedures and hemostasis management.
Side-by-side fundamentals
| Metric | EW | HAE | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $89.79 | $108.80 | |
| Market cap as of 2026-08-24 | $51.8B | $5.0B | |
| P/E as of 2026-08-24 | 53.52 | 43.22 | HAE lower |
| PEG as of 2026-08-24 | 3.54 | n/a | |
| Net margin as of 2026-08-24 | +15.4% | +7.1% | EW higher |
| Gross margin as of 2026-08-24 | +77.8% | +59.1% | EW higher |
| Operating margin as of 2026-08-24 | +18.2% | +11.9% | EW higher |
| ROE as of 2026-08-24 | +9.7% | +11.3% | HAE higher |
| ROA as of 2026-08-24 | +7.4% | +4.0% | EW higher |
| Debt / equity as of 2026-08-24 | 0.06 | 1.40 | EW lower |
| Revenue growth (YoY) as of 2026-08-24 | +14.6% | +0.4% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +4.5% | EW higher |
| Beta as of 2026-08-24 | 0.85 | 0.63 | |
| 1-year return as of 2026-08-21 close | +10.6% | +101.6% | HAE higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.